Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan
· Delayed Price · Currency is TWD 78.50
-4.20 (-5.08%)
Apr 29, 2026, 2:00 PM CST
Steminent Biotherapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | - | - | 0.94 | 0.64 | 2.12 | Upgrade
|
| Revenue Growth (YoY) | - | - | 47.96% | -70.01% | -95.88% | Upgrade
|
| Cost of Revenue | 0.79 | 6.09 | 1.98 | 9.57 | 3.87 | Upgrade
|
| Gross Profit | -0.79 | -6.09 | -1.04 | -8.93 | -1.75 | Upgrade
|
| Selling, General & Admin | 57.6 | 45.83 | 62.7 | 33.87 | 25.76 | Upgrade
|
| Research & Development | 115.28 | 110.38 | 67.73 | 55.41 | 48.09 | Upgrade
|
| Operating Expenses | 172.87 | 156.21 | 130.42 | 89.28 | 73.85 | Upgrade
|
| Operating Income | -173.66 | -162.3 | -131.46 | -98.21 | -75.6 | Upgrade
|
| Interest Expense | -2.15 | -1.92 | -1.78 | -0.9 | -1.33 | Upgrade
|
| Interest & Investment Income | 2.51 | 4.13 | 2.96 | 0.85 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.87 | 1.34 | -0.02 | 2.8 | -0.8 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.02 | 0.14 | 1.08 | 9.99 | -46.1 | Upgrade
|
| EBT Excluding Unusual Items | -174.15 | -158.6 | -129.23 | -85.47 | -123.75 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0 | Upgrade
|
| Pretax Income | -174.15 | -158.6 | -129.23 | -85.47 | -124.2 | Upgrade
|
| Income Tax Expense | -0.11 | 0.15 | - | - | - | Upgrade
|
| Net Income | -174.04 | -158.75 | -129.23 | -85.47 | -124.2 | Upgrade
|
| Net Income to Common | -174.04 | -158.75 | -129.23 | -85.47 | -124.2 | Upgrade
|
| Shares Outstanding (Basic) | 59 | 56 | 48 | 44 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 59 | 56 | 48 | 44 | 35 | Upgrade
|
| Shares Change (YoY) | 5.49% | 15.42% | 8.84% | 26.27% | 17.57% | Upgrade
|
| EPS (Basic) | -2.95 | -2.84 | -2.67 | -1.92 | -3.52 | Upgrade
|
| EPS (Diluted) | -2.95 | -2.84 | -2.67 | -1.92 | -3.52 | Upgrade
|
| Free Cash Flow | -140.07 | -226.57 | -142.27 | -71.52 | -55.71 | Upgrade
|
| Free Cash Flow Per Share | -2.38 | -4.05 | -2.94 | -1.61 | -1.58 | Upgrade
|
| Gross Margin | - | - | -110.10% | - | -82.32% | Upgrade
|
| Operating Margin | - | - | -13970.14% | -15442.14% | -3564.12% | Upgrade
|
| Profit Margin | - | - | -13733.16% | -13439.31% | -5855.78% | Upgrade
|
| Free Cash Flow Margin | - | - | -15119.02% | -11245.28% | -2626.69% | Upgrade
|
| EBITDA | -155.03 | -158.14 | -129.51 | -96.59 | -71.91 | Upgrade
|
| D&A For EBITDA | 18.63 | 4.15 | 1.95 | 1.62 | 3.69 | Upgrade
|
| EBIT | -173.66 | -162.3 | -131.46 | -98.21 | -75.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.